An observational study in Overactive Bladder, sponsored by Stimuli Technology. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Stimuli Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Urinary Bladder, Overactive with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Italy.
Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 28th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 30 studies in Urinary Bladder, Overactive with a site in Italy are open now. Recruiting first, the newest first:
University of Naples · Sites in Italy
Ages 50–80
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Median enrollment 884 across the 24 interventional studies, 312 across the 3 observational. Of the 27 that completed or were terminated, 16 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 30 have an industry lead sponsor. The 10 most frequent:
Stimuli Technology is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Stimuli Technology has 3 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Bladder, Overactive with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07305298University of NaplesMirabegron in Patients With Age-Related Macular Degeneration | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management. Preliminary studies have shown a favorable safety and efficacy profile. The goal of the present registry is to collect data among an important number of patients to assess the efficacy, safety and potential predictive factors of success in a current clinical setting over a total period of 1 year.
Age ≥ 18 years Overactive bladder symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
Subjective improvement
The Patient Global Impression of Improvement (PGI-I) uses a 7-point scale, where post-treatment condition is rated as follows: 1. = Very much better 2. = Much better 3. = A little better 4. = No change 5. = A little worse 6. = Much worse 7. = Very much worse. For analysis, patients with a PGI-I score of 1, 2, or 3 are typically considered responders, reflecting meaningful improvement.
Time frame: 3 and 12 months
Patient-reported Outcomes Measures (PROMs)
Urinary symptoms by filling up International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) which is a questionnaire intended to assess female storage, voiding and incontinence symptoms. Lower scores are typically associated with reduced symptom severity.
Time frame: 0; 3 and 12 months
Patient-reported Outcomes Measures (PROMs)
Urinary symptoms by filling up International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS) which is a questionnaire intended to assess male storage, voiding and incontinence symptoms. Lower scores are typically associated with reduced symptom severity.
Time frame: 0; 3 and 12 months
Quality of life measures
By filling up International Consultation on Incontinence Questionnaire - OAB quality of life (ICIQ-OABqol) which is a questionnaire evaluating quality of life in patients with overactive bladder. Lower scores are typically associated with improved quality of life.
Time frame: 0; 3 and 12 months
Patient-reported Outcomes Measures (PROMs)
By filling up International Consultation on Incontinence Questionnaire - Bowel (ICIQ-B) which is a questionnaire for evaluating symptoms of anal incontinence. Lower scores are typically associated with reduced symptom severity.
Time frame: 0; 3 and 12 months
Evaluation of voiding frequency
Evaluation of daytime voiding frequency averaged over three days from bladder diary entries
Time frame: 0; 3 and 12 months
Evaluation of urgency
Evaluation of daily urgency episodes averaged over three days from bladder diary entries
Time frame: 0; 3 and 12 months
Evaluation of nocturia
Evaluation of nocturia episodes averaged over three days from bladder diary entries
Time frame: 0; 3 and 12 months
Evaluation of urgency urinary incontinence
Evaluation of urgency urinary incontinence episodes averaged over three days from bladder diary entries
Time frame: 0; 3 and 12 months
Evaluation of adverse events
Patients will be asked whether they experienced any adverse events during treatment. Patient responses will be collected and described qualitatively, enabling the identification of the types of adverse events reported as well as the frequency of their occurrence.
Time frame: 3 and 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Oct 2028, 43 months after the start.
Of 59 observational studies under Urinary Bladder, Overactive, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 43 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Oct 2027 → Oct 2028 and completion Oct 2027 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stimuli Technology